PRESS RELEASE 2012

Ferring’s European Marketing Authorisation Application for controlled release misoprostol vaginal delivery system for the induction of labour accepted for review

By pulse in PRESS RELEASE 2012 on 05 November 2012

Ferring Pharmaceuticals announced today that it has received confirmation from European health authorities that the Marketing Authorisation…

Ferring Announces FDA Acceptance of NDA Filing for Controlled Release Misoprostol Vaginal Insert for Decreasing Time to Vaginal Delivery in Women

By pulse in PRESS RELEASE 2012 on 23 October 2012

Ferring Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA)…

New study showed desmopressin melt reduced sleep disruption in bedwetting children

By pulse in PRESS RELEASE 2012 on 12 October 2012

Preliminary results from a new, prospective study presented today at the first Joint Congress of the International Children’s Continence…

Fonds de solidarité FTQ, CTI Life Sciences Fund and Ferring Pharmaceuticals Create a New Biotech in Québec

By pulse in PRESS RELEASE 2012 on 05 October 2012

The Fonds de solidarité FTQ (the “Fonds”), CTI Life Sciences Fund and Ferring Pharmaceuticals are pleased to announce…

FDA approves Ferring’s PREPOPIK™ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) for colonoscopy prep

By pulse in PRESS RELEASE 2012 on 17 July 2012

The U.S. Food and Drug Administration (FDA) granted Ferring Pharmaceuticals Inc. approval to market PREPOPIK (sodium picosulfate, magnesium…

Ferring Pharmaceuticals Acquires Licensing Rights for Elobixibat from Albireo AB

By pulse in PRESS RELEASE 2012 on 03 July 2012

Ferring Pharmaceuticals (Ferring) and Albireo AB (Albireo) announced today that they have signed a license agreement under which Ferring has…

Ferring Pharmaceuticals donates $10 million to the Salk Institute for Biological Studies

By pulse in PRESS RELEASE 2012 on 07 June 2012

Ferring Pharmaceuticals, a global, specialty biopharmaceuticals company, has donated $10 million to support research at the Salk Institute…

New data show that FIRMAGON® (degarelix) is non-inferior to the combination of goserelin plus bicalutamide at reducing prostate volume in patients with advanced hormone-dependent prostate cancer while offering better relief from lower urinary tract symptoms

By pulse in PRESS RELEASE 2012 on 28 February 2012

Two new studies presented at the 27th Annual European Association of Urology (EAU) Congress reported that…

Ferring announces new million euro educational initiative with International Federation of Fertility Societies (IFFS) and Elsevier

By pulse in PRESS RELEASE 2012 on 08 February 2012

World leader in fertility treatments, Ferring Pharmaceuticals, announced today at the 2012 Updates in Infertility Treatment (UIT) meeting that…